As previously disclosed on November 14, 2024, Allarity’s (ALLR) cash position is expected to support operations into 2026. The $2.5 million civil penalty payment does not affect the Company’s financial outlook, including its ability to execute its Phase 2 program in advanced ovarian cancer, initiate the upcoming Phase 2 trial of stenoparib in combination with temozolomide for recurrent small cell lung cancer, or proceed with its share repurchase plan.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALLR:
- Biotech Alert: Searches spiking for these stocks today
- Allarity announes Phase 2 trial of stenoparib with temozolomide
- Allarity announces board authorization of $5M share repurchase program
- Allarity announces dismissal of securities class action lawsuit
- Allarity to begin enrollments for Phase 2 protocol to advance stenoparib